Erasca Shares Plunge 48% on Lead Asset IP Challenge; Law Firm Investigates Misleading Claims
ERAS has more than doubled off its 52-week low of $1.06.
Summary
Erasca shares plunged 48% on April 28, wiping out $2.8 billion in market value, after the company disclosed a legal challenge to the intellectual property of its lead asset, ERAS-0015, by Revolution Medicines. This follows an 8-K filing on April 27 detailing Revolution Medicines' claims of patent infringement and trade secret misappropriation. Shareholder rights law firm Hagens Berman has now launched an investigation into whether Erasca misled investors about the viability of ERAS-0015's intellectual property. This IP dispute directly threatens the company's most important product candidate and introduces significant litigation risk and uncertainty.
At the time of this announcement, ERAS was trading at $12.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.9B. The 52-week trading range was $1.06 to $24.28. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: PR Newswire.